Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can intensive speech therapy rewire speech in children with rare genetic conditions?

NCT ID NCT07815249

Symptom relief Sponsor: Murdoch Childrens Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether four weeks of intensive motor speech therapy can improve speech accuracy in children who have childhood apraxia of speech along with a rare genetic condition. The study enrolls up to 20 children aged 3 to 16. Each child receives 12 sessions of either Rapid Syllable Transition Treatment or Dynamic Temporal and Tactile Cueing, assigned based on age and speech ability, and completes speech assessments before, during, and after therapy. The study tracks each child individually and does not compare the two therapies against each other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
motor speech therapy, either Rapid Syllable Transition Treatment (ReST) or Dynamic Temporal and Tactile Cueing (DTTC)
What this could lead to
If it works, this could give families and speech therapists clearer evidence for using intensive motor speech therapy in children with rare genetic conditions and apraxia of speech.
What could go wrong
This is a small study of 20 children that looks at each child individually rather than comparing groups, so results may not apply broadly. Children may improve for reasons unrelated to therapy, and gains may not carry over to everyday speech.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 16 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged between 3 and 16 years, with a confirmed genetic condition and a diagnosis of childhood apraxia of speech; English as the primary language at home; able to participate in speech therapy 3 times per week for 4 weeks Exclusion Criteria: * Diagnosis of an acquired brain or movement condition likely to affect speech; currently receiving motor speech therapy in the community; diagnosis of a behavioural condition likely to impact engagement (i.e., unable to participate for 45 minutes, unable to focus attention at the speech therapist's face for a few minutes at a time, unable to say any sounds and/or use gesture, unable to try to copy speech therapist; intolerant to touch (if touch cues are needed for DTTC)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood apraxia of speech are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

apraxia childhood apraxia of speech communication disorder hereditary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood apraxia of speech Genetic condition

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Murdoch Children's Research Institute

    RECRUITING

    Melbourne, Victoria, 3052, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.